EMERYVILLE, Calif., May 30 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. , today announced that it has appointed David C. Chou, Ph.D., to the position of Director of Chemistry, Manufacturing and Controls (CMC). He will report to Karl G. Trass, Vice President of Regulatory Affairs and Quality Assurance.
Chou, 50, has over 20 years experience in the pharmaceutical and quality management disciplines and has led numerous projects from R&D to commercialization. Most recently, he was Senior Director for Chemistry, Manufacturing and Controls at PharmaEngine in Taipei, Taiwan. Prior to that, he worked at Oculex Pharmaceuticals, Inc. as Director of Analytical and Product Development, and at SUGEN, Inc. (then a subsidiary of Pharmacia) as Associate Director, Analytical Development. Earlier in his career, he worked in Research and Development and in the Quality Control Department of Hoffmann-La Roche, and he began his career as a research fellow at the American Health Foundation. Chou holds a Ph.D. in Analytical Chemistry from the City University of New York.
Karl Trass said, “This is a significant position for NTI within the area of manufacturing, which we believe will enhance the prospects of moving our product candidates through clinical trials and approval. Given our broad contract manufacturing relationships for both of our Phase III clinical programs, David’s technical expertise will be critical as we seek to continue to registration and commercialization.”
He also said, “David brings to NTI a wealth of CMC experience including analytical methods development, scale up, GMP manufacturing, and validation. David’s prior technical and managerial experience will enhance our relationships with vendors and the regulatory agencies.”
Chou said, “NTI has two important programs in Phase III: Viprinex(TM) for acute ischemic stroke and XERECEPT(R) for peritumoral brain edema. It is imperative we provide products that have been manufactured according to worldwide GMP standards. This is essential for the safety of clinical trial subjects and for potential commercialization. NTI is committed to the highest excellence in the manufacture of its products and I am pleased to be a member of the team.”
About Neurobiological Technologies, Inc.
NTI is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI’s experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia and we may seek partnerships with pharmaceutical and biotechnology companies to assist us.
NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including, changes to our management team, our reliance on third-party manufactures and clinical trials and the regulatory approval process and other risks detailed from time to time in our Securities and Exchange Commission filings. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We disclaim, however, any intent or obligation to update these forward-looking statements.
Neurobiological Technologies, Inc.
CONTACT: Paul E. Freiman, President & CEO of Neurobiological Technologies,Inc., +1-510-595-6000; or Cheryl Schneider, VP - Investor Relations ofPorter, LeVay & Rose, Inc., for Neurobiological Technologies, Inc.
Web site: http://www.ntii.com//
